Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer News

News
Radiomics and AI Advance NSCLC Staging Precision
03/10/2025
Juliet Gallagher
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in...
03/10/2025
Journal of Clinical Pathways
News
Machine Learning Identifies Key Genomic Markers to Predict CPI Outcomes in NSCLC
03/06/2025
Grace Taylor, MS, MA
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study...
03/06/2025
Journal of Clinical Pathways
News
Evaluating Cost-Effectiveness of First-Line Cemiplimab Therapy in Advanced NSCLC
03/05/2025
Juliet Gallagher
A recent cost-effectiveness analysis published in Journal of Managed Care & Specialty Pharmacy comparing cemiplimab plus chemotherapy (CCT) with pembrolizumab plus chemotherapy (PCT) as first-line treatment for advanced non-small cell lung...
A recent cost-effectiveness analysis published in Journal of Managed Care & Specialty Pharmacy comparing cemiplimab plus chemotherapy (CCT) with pembrolizumab plus chemotherapy (PCT) as first-line treatment for advanced non-small cell lung...
A recent cost-effectiveness...
03/05/2025
Journal of Clinical Pathways
News
Durvalumab Immunotherapy Shows Survival Benefit but Fails Cost-Effectiveness in Key Markets
02/13/2025
Lisa Kuhns, PhD, MD
Durvalumab immunotherapy improves survival in unresectable stage III non-small cell lung cancer (NSCLC), but its high cost makes it prohibitive globally under current pricing models, according to study results published in JAMA Network Open.
Durvalumab immunotherapy improves survival in unresectable stage III non-small cell lung cancer (NSCLC), but its high cost makes it prohibitive globally under current pricing models, according to study results published in JAMA Network Open.
Durvalumab immunotherapy...
02/13/2025
Journal of Clinical Pathways
News
Machine Learning Algorithms Offer Alternative to Imaging in NSCLC Staging
02/03/2025
Juliet Gallagher
A recent study published in Journal of Thoracic Disease demonstrated the effectiveness of artificial intelligence (AI) in predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC).
A recent study published in Journal of Thoracic Disease demonstrated the effectiveness of artificial intelligence (AI) in predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC).
A recent study published in...
02/03/2025
Journal of Clinical Pathways
News
Artificial Intelligence Predicts Survival Outcomes in Advanced NSCLC
01/21/2025
Juliet Gallagher
A recent study published in BMC Cancer developed an artificial intelligence (AI)-based model to predict survival outcomes for patients with advanced non-small cell lung cancer (NSCLC), offering a step forward in personalized medicine.
A recent study published in BMC Cancer developed an artificial intelligence (AI)-based model to predict survival outcomes for patients with advanced non-small cell lung cancer (NSCLC), offering a step forward in personalized medicine.
A recent study published in BMC...
01/21/2025
Journal of Clinical Pathways
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
Stephanie Holland
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
FDA Approved Lazertinib Plus Amivantamab for Advanced Non-Small Cell Lung Cancer With EGFR Mutations
08/20/2024
Allison Casey
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib...
08/20/2024
Oncology
News
FDA Grants Approval to Neoadjuvant/Adjuvant Durvalumab for Patients With Resectable Non-Small Cell Lung Cancer
08/16/2024
Stephanie Holland
The FDA has approved durvalumab plus a platinum-containing regimen followed by surgery and single-agent durvalumab for adult patients with resectable non-small cell lung cancer with no known EGFR mutations or ALK rearrangements.
The FDA has approved durvalumab plus a platinum-containing regimen followed by surgery and single-agent durvalumab for adult patients with resectable non-small cell lung cancer with no known EGFR mutations or ALK rearrangements.
The FDA has approved durvalumab...
08/16/2024
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Stephanie Holland
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use